Our Publications
Show: AllPeer ReviewedNon Peer Reviewed
14 publications from 2018
Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, Malladi RK, Paneesha S, Pawson R, Quinn M, Raj K, Richardson D, Robinson S, Russell N, Snowden J, Sureda A, Tholouli E, Thomson K, Watts M, Wilson KM., UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy., Journal of clinical apheresis, 33, (1), 2018, p46-59
Breitkreutz I, Podar K, Figueroa-Vazquez V, Wilhelm S, Hayden PJ, Anderson KC, Raab MS., The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma., Annals of hematology, 97, (5), 2018, p839-849
McDonald, Laura, McCarthy, Peter, Khan, Mohammad, Hogan, Patrick, Kelleher, Eileen C., Murphy, Philip, Quinn, John, Desmond, Ronan, McHugh, Johnny, Strickland, Melanie, Cahill, Mary, Maung, Su Wai, Keohane, Clodagh, O'Neill, Desmond, Ryan, Daniel, Mykytiv, Vitaliy, Enright, Helen, Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older, 132, (Supplement 1), 2018, pp5515-5515
, Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia, Leukemia, 2018
Auner, H.W. and Iacobelli, S. and Sbianchi, G. and Knol-Bout, C. and Blaise, D. and Russell, N.H. and Apperley, J.F. and Pohlreich, D. and Browne, P.V. and Kobbe, G. and Isaksson, C. and Lenhoff, S. and Scheid, C. and Touzeau, C. and Jantunen, E. and Anagnostopoulos, A. and Yakoub-Agha, I. and Tanase, A. and Schaap, N. and Wiktor-Jedrzejczak, W. and Krejci, M. and Schönland, S.O. and Morris, C. and Garderet, L. and Kröger, N., Melphalan 140 mg/m2or 200 mg/m2for autologous transplantation in myeloma: Results from the collaboration to collect autologous transplant outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT chronic malignancies working party, Haematologica, 103, (3), 2018, p514-521
Sahebi, F. and Iacobelli, S. and Sbianchi, G. and Koster, L. and Blaise, D. and Reményi, P. and Russell, N.H. and Ljungman, P. and Kobbe, G. and Apperley, J. and Trneny, M. and Krejci, M. and Wiktor-Jedrzejczak, W. and Sanchez, J.F. and Schaap, N. and Isaksson, C. and Lenhoff, S. and Browne, P. and Scheid, C. and Wilson, K.M.O. and Yakoub-Agha, I. and Muñiz, S.G. and Schönland, S. and Morris, C. and Garderet, L. and Kröger, N., Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents, Biology of Blood and Marrow Transplantation, 24, (5), 2018, p930-936
Appleby, N., O"Brien, D., Quinn, F.M., Smyth, L., Kelly, J., Parker, I., Scott, K., Cahill, M.R., Crotty, G., Enright, H., Hennessy, B., Hodgson, A., Leahy, M., O"Leary, H., O"Dwyer, M., Hayat, A., Vandenberghe, E.A., Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL, Leukemia and Lymphoma, 59, (6), 2018, p1338-1347
Dreger, P., Michallet, M., Bosman, P., Dietrich, S., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J., Niederwieser, D., Müller, L., Vandenberghe, E., Scortechini, I., Schoemans, H., Andersen, N.S., Finke, J., Russo, D., Ljungman, P., Passweg, J., van Gelder, M., Durakovic, N., Labussiere-Wallet, H., Berg, T., Wulf, G., Bethge, W., Bunjes, D., Stilgenbauer, S., Canepari, M.E., Schaap, M., Fox, C.P., Kröger, N., Montoto, S., Schetelig, J., Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties, Bone Marrow Transplantation, 2018, p1-9
Frawley, T., O'Brien, C.P., Conneally, E., Vandenberghe, E., Percy, M., Langabeer, S.E., Haslam, K., Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms, Genetic Testing and Molecular Biomarkers, 22, (2), 2018, p98-103
Avivi, I., Boumendil, A., Finel, H., Nagler, A., de Sousa, A.B., Santasusana, J.M.R., Vandenberghe, E., Afanasyev, B., Bordessoule, D., Moraleda, J.M., Garcia, E.C., Pohlreich, D., Garcia, G.G., Thomson, K., Or, R., Beelen, D., Zuffa, E., Giebel, S., Berthou, C., Salles, G., Melpignano, A., Montoto, S., Dreger, P., Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation, Bone Marrow Transplantation, 2018, p1-9
Bierings, M. and Bonfim, C. and Peffault De Latour, R. and Aljurf, M. and Mehta, P.A. and Knol, C. and Boulad, F. and Tbakhi, A. and Esquirol, A. and McQuaker, G. and Sucak, G.A. and Othman, T.B. and Halkes, C.J.M. and Carpenter, B. and Niederwieser, D. and Zecca, M. and Kröger, N. and Michallet, M. and Risitano, A.M. and Ehninger, G. and Porcher, R. and Dufour, C. and Bonfirm, C. and Socié, G. and Gurman, G. and Ghavamzadeh, A. and Hamladji, R.-M. and van Lint, M.T. and Stepensky, P. and Koh, M. and Ozkurt, Z.N. and Veelken, J.H. and Bunjes, D. and Beelen, D. and Campos, A. and Robinson, S. and Alessandrino, E.P. and Unal, A. and Fernandez Navarro, J.M. and Mufti, G.J. and Velardi, A. and Passweg, J. and Apperley, J. and Sengeloev, H. and Ljungman, P. and Foá, R. and Alegre, A. and Espiga, C.R. and Cornelissen, J.J. and Di Bartolomeo, P. and Cordonnier, C. and Browne, P. and Jubert, C. and Gastl, G. and Pierelli, L. and Johansson, J.-E. and Fagioli, F. and Moraleda, J. and Zuckerman, T. and Bazarbachi, A. and Sedlacek, P. and Rössig, C. and Wynn, R.F. and Hallek, M. and Toren, A. and Zudaire, T. and Clausen, J. and Spencer, A. and Grazon Lopez, S. and Schots, R. and Komarnicki, M. and González Muniz, S. and Vitek, A. and Rambaldi, A. and Merli, F. and Rubio, M.T. and Rossig, C. and Cabrera MarÃn, J.R. and Porto, F. and Kerre, T. and Metzner, B. and Stein, J. and Bertrand, Y. and Ciceri, F. and Chybicka, A. and Diez-Martin, J.L. and Bayoumy, M. and de la Fuente, J. and Fegueux, N., Transplant results in adults with Fanconi anaemia, British Journal of Haematology, 180, (1), 2018, p100-109
Mcdonnell, C.J. and Soule, E.E. and Walsh, P.T. and O'donnell, J.S. and Preston, R.J.S., The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease, Seminars in Thrombosis and Hemostasis, 2018, p167 - 175
Fallon, P.G. and Lavin, M. and O'Donnell, J.S., SIPPET: insights into factor VIII immunogenicity, Journal of Thrombosis and Haemostasis, 16, (1), 2018, p36-38
Byrne CJ, Parton T, McWhinney B, Fennell JP, O'Byrne P, Deasy E, Egan S, Enright H, Desmond R, Ryder SA, D'Arcy DM, McHugh J, Roberts JA, Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy, Journal of Antimicrobial Chemotherapy, 73, (4), 2018, p995 - 1003